A jury in Arkansas ruled that Johnson & Johnson officials used deceptive tactics to market antipsychotic drug Risperdal, misleading doctors about the drug’s risks and improperly marketing it for unapproved uses, Bloomberg reports.
The decision in Arkansas marks the third such jury verdict against Johnson & Johnson over allegations that the pharmaceutical giant concealed Risperdal’s risks and tricked Medicaid regulators into paying more than they should have for the medication.
Juries also decided against the company in Louisiana and South Carolina.
A total ...
continue reading...